Uncategorized
MindMaze Therapeutics appoints strategic advisor for US growth

MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States.
“John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As we scale in the United States, his counsel will help us achieve our mission to reach more patients in need of precision neurotherapeutics wherever they may be.”
Dr Krakauer is the original scientific creator of MindPod, MindMaze Therapeutics’ precision upper-limb rehabilitation system, and one of the world’s most cited researchers in motor neuroscience, stroke recovery, and neurorehabilitation. He holds the John C Malone Professorship in Neurology, Neuroscience, and Physical Medicine and Rehabilitation at The Johns Hopkins University School of Medicine, and directs both the Brain, Learning, Animation, and Movement (BLAM) Lab and the Centre for Restorative Neurotechnology (CRN) at the Champalimaud Foundation in Lisbon, Portugal. His foundational work establishing the high-dose, high-intensity paradigm, which is the scientific basis of the MindMaze platform, has reshaped how the field approaches neuroplasticity-driven recovery.
“The clinical case for high-dose, high-intensity neurorehabilitation is now unambiguous: the brain is a learning organ, and recovery depends on delivering the right dose and intensity of training. Health systems have historically struggled to do so, lacking a scalable platform that could deliver it reliably across every care setting, including the home. MindMaze Therapeutics has spent years turning that science into a platform clinicians can actually deploy across the care continuum, while confirming in the real world what the science always suggested: dose and intensity drive recovery. This advisory role lets me stay closely engaged in that mission while pushing the underlying research forward,” said Dr Krakauer.
The appointment follows a period of significant momentum for MindMaze Therapeutics, including a two-year, multi-site real-world evidence programme that demonstrated significant improvements in patient mobility and self-care, a 60% increase in therapy delivered per day and 17% higher community discharge rates compared with standard care, while 87% of patients found the neurotherapy enjoyable. The company has also established a US headquarters and Patient Experience Center at The Pearl in Charlotte’s Innovation District, and earlier this year announced a go-to-market partnership with Vibra Healthcare.
The post MindMaze Therapeutics appoints strategic advisor for US growth appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read